GSK3-XIII and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

GSK3-XIII has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for GSK3-XIII and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorganic & medicinal chemistry letters, 2009, Jul-01, Volume: 19, Issue:13 The identification of a novel series of Aurora kinase inhibitors and exploitation of their SAR is described. Replacement of the initial quinazoline core with a pyrimidine scaffold and modification of substituents led to a series of very potent inhibitors of cellular proliferation. MK-0457 (VX-680) has been assessed in Phase II clinical trials in patients with treatment-refractory chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) containing the T315I mutation. Topics: Aurora Kinases; Cell Line, Tumor; Computer Simulation; Crystallography, X-Ray; Drug Design; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutant Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Structure-Activity Relationship	2009

Article

Year

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

Bioorganic & medicinal chemistry letters, 2009, Jul-01, Volume: 19, Issue:13

The identification of a novel series of Aurora kinase inhibitors and exploitation of their SAR is described. Replacement of the initial quinazoline core with a pyrimidine scaffold and modification of substituents led to a series of very potent inhibitors of cellular proliferation. MK-0457 (VX-680) has been assessed in Phase II clinical trials in patients with treatment-refractory chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) containing the T315I mutation.

Topics: Aurora Kinases; Cell Line, Tumor; Computer Simulation; Crystallography, X-Ray; Drug Design; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutant Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Structure-Activity Relationship

2009